NCT00227591View on ClinicalTrials.gov

Lenalidomide and Prednisone in Treating Patients With Myelofibrosis

PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
Essential ThrombocythemiaPolycythemia VeraPrimary Myelofibrosis
Interventions
DRUG

lenalidomide

Given orally (PO)

DRUG

prednisone

Given PO

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

02215

Eastern Cooperative Oncology Group, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00227591 - Lenalidomide and Prednisone in Treating Patients With Myelofibrosis | Biotech Hunter | Biotech Hunter